Specify a stock or a cryptocurrency in the search bar to get a summary
Liquidia Technologies Inc
LQDALiquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina. Address: 419 Davis Drive, Morrisville, NC, United States, 27560
Analytics
WallStreet Target Price
25.33 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures LQDA
Dividend Analytics LQDA
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History LQDA
Stock Valuation LQDA
Financials LQDA
Results | 2019 | Dynamics |